The current indications for TPO-RA include the treatment of chronic immune thrombocytopenia (ITP) in patients with inadequate response to prior therapy using options such as avatrombopag (AVA), eltrombopag (EPAG), herombopag, and romiplostim; thrombocytopenia with chronic liver disease (CLD) in adult patients who are scheduled for surgery using AVA and lusutrombopag; SAA using EPAG, hetrombopag, and romiplostim; and interferon-based hepatitis C using EPAG [9–11]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.